Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001273885-26-000002
Filing Date
2026-05-11
Accepted
2026-05-11 16:30:17
Documents
1
Period of Report
2026-05-11

Document Format Files

Seq Description Document Type Size
1 form4-05112026_040505.html 4  
1 form4-05112026_040505.xml 4 16647
  Complete submission text file 0001273885-26-000002.txt   18096
Mailing Address C/O ATEA PHARMACEUTICALS, INC. 225 FRANKLIN STREET SUITE 2100 BOSTON MA
Business Address
BERGER FRANKLIN M (Reporting) CIK: 0001273885 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38542 | Film No.: 26963674

Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Issuer) CIK: 0001645666 (see all company filings)

EIN.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)